Business·Industry

“LTA Contracts Typically Last 5 Years… Focus on Ensuring Medium- to Long-Term Stability”—SK hynix Conference Call

JAEMIN SONG
2026-07-29 09:34:54
[Edaily JAEMIN SONG Choi Oh-hyun Reporter] “The long-term supply agreement (LTA) we are currently discussing is based on a five-year term, but the specific contract duration and terms may vary depending on the customer and product characteristics. Rather than adopting a single pricing structure, we are consulting with customers to develop a model that can respond to market volatility, focusing on securing mid- to long-term business stability for both our customers and our company. While it is difficult to specify the exact proportion of total sales accounted for by LTAs, we plan to operate at an appropriate level based on market demand. We will enhance the downside stability of our earnings while maintaining the flexibility to grow when market conditions are favorable. We are already continuing long-term contractual partnerships with major customers, including NVIDIA, based on HBM, and through these partnerships, we will manage stability and profitability in a balanced manner.”

…SK hynix Q2 2026 Conference Call


A view of SK hynix’s headquarters in Icheon, Gyeonggi Province. (Photo: Yonhap News)

Economy

Corporation

IT·Science

Economy

NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year

#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
2026-08-19 10:02:44

Corporation

Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs

Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
2026-08-19 09:54:02

IT·Science

LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology

# LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
2026-08-19 10:20:03